SRPT News and Press, Sarepta Therapeutics Inc. From 06/17/24

2024-06-17 13:29:18 ET Summary Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Roche initiated the process for Elevidys marketing authorization application in Europe, expected to be completed by H1 2024. ...

2024-06-16 11:15:16 ET Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficie...

2024-06-14 15:00:00 ET More on the markets SPY Is Sub-Optimal For Long-Term Diversified Investors S&P 500 Peaks And VIX Valleys As Market Signals Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) Citi says ETFs will engulf U.S. as...

2024-06-13 15:15:01 ET Citigroup analyst issues BUY recommendation for SRPT on June 13, 2024 01:18PM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.865 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...

2024-06-13 11:00:06 ET Brian Skorney from Robert W. Baird issued a price target of $170.00 for SRPT on 2024-06-13 10:14:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $124. The overall price target consensus is at $...

2024-06-13 09:00:00 ET U.S. stock index futures on Thursday were mixed . Wall Street's benchmark and tech-heavy gauges were on track to extend their gains from the previous session, but its blue-chip average looked set to add onto losses. Here are some stocks to watch on Thursday: ...

2024-06-13 07:15:05 ET Barclays analyst issues OVERWEIGHT recommendation for SRPT on June 13, 2024 05:41AM ET. The previous analyst recommendation was Overweight. SRPT was trading at $119.98 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-13 07:00:26 ET More on Pfizer, Roche, etc. Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates ...

2024-06-13 07:00:07 ET Gena Wang from Barclays issued a price target of $185.00 for SRPT on 2024-06-13 05:41:00. The adjusted price target was set to $185.00. At the time of the announcement, SRPT was trading at $119.98. The overall price target consensus is at $152.45 w...

2024-06-07 09:00:09 ET Kostas Biliouris from BMO Capital issued a price target of $170.00 for SRPT on 2024-06-07 07:23:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $117.44. The overall price target consensus is at...